Navigation Links
Ventas Enters Agreement to Sell Common Stock
Date:1/29/2008

idiaries, "Kindred"), Brookdale Living Communities, Inc. (together with its subsidiaries, "Brookdale") and Alterra Healthcare Corporation (together with its subsidiaries, "Alterra") to meet and/or perform their obligations to indemnify, defend and hold the Company harmless from and against various claims, litigation and liabilities under the Company's respective contractual arrangements with Kindred, Brookdale and Alterra; (c) the ability of the Company's operators, tenants, borrowers and managers, as applicable, to maintain the financial strength and liquidity necessary to satisfy their respective obligations and liabilities to third parties, including without limitation obligations under their existing credit facilities; (d) the Company's success in implementing its business strategy and the Company's ability to identify, underwrite, finance, consummate and integrate diversifying acquisitions or investments, including those in different asset types and outside the United States; (e) the nature and extent of future competition; (f) the extent of future or pending healthcare reform and regulation, including cost containment measures and changes in reimbursement policies, procedures and rates; (g) increases in the Company's cost of borrowing; (h) the ability of the Company's operators and managers, as applicable, to deliver high quality services, to attract and retain qualified personnel and to attract residents and patients; (i) the results of litigation affecting the Company; (j) changes in general economic conditions and/or economic conditions in the markets in which the Company may, from time to time, compete; (k) the Company's ability to pay down, refinance, restructure and/or extend its indebtedness as it becomes due; (l) the movement of interest rates and the resulting impact on the value of and the accounting for the Company's interest rate swap agreement; (m) the Company's ability and willingness to maintain its qualification as a REIT due to economic, marke
'/>"/>
SOURCE Ventas, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance
2. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
3. Ventas Appoints Brush SVP - Senior Housing Development and Operations
4. Ventas Announces 2007 Third Quarter Earnings Release Date and Conference Call
5. Ventas Board Names Ronald G. Geary Audit Committee Chair; Appoints Douglas Crocker II to Fill Vacancy on Audit Committee
6. Ventas Declares Regular Quarterly Dividend of $0.475 Per Share
7. Inverness Medical Innovations Enters Into a Definitive Agreement to Acquire Matria Healthcare, Inc.
8. Excessive overtriage in US trauma centers overwhelming system resources, delaying patient care
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. New Company Enters Companion Animal Veterinary Medicine Channel
11. Millennium Enters Into $600,000 Product Development Agreement to Fund Product Development for the $20,000,000 Purchase Agreement with Provider Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2008)...Newswire/ -- NursingCenter.com, the premier site,...eviewed content, has been,updated to improve the ...,users. Powered by Lippincott Williams & Wilki... peer-reviewed continuing education activities and... leading nursing journals.,Lippincott Williams &a...
(Date:11/21/2008).... 21 Today, prescription...on in treating 88 percent of patients suffering ch...ated for a chronic condition account for 96 percen... of all medical costs. A proprietary new pharmacy...Solutions, Inc. (NYSE: MHS ) significantly reduc...
(Date:11/21/2008)...deadly diseaseits cause remains a mysteryswept int...with citizens, soldiers and refugees of the war th...lled with corpses, social order broke down. Over t...d Athens lost a third of its population. It lost t...ing of the end of the Golden Age of Greece. , T...
(Date:11/21/2008)...Newswire-FirstCall/ -- Symmetry Medical Inc. (NYSE...cts to the global orthopedic device industry and o.... Moore, President and Chief Executive Officer, an...nancial Officer, are scheduled to present at the 2... The New York Palace Hotel on Wednesday, December ...
Breaking Medicine News(10 mins):Health News:NursingCenter.com Launches New Features to Improve User Experience 2Health News:NursingCenter.com Launches New Features to Improve User Experience 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 2Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 3Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 4Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 5Health News:New Data: Advanced Pharmacy Model Significantly Reduces Gaps in Care for Patients with Chronic and Complex Conditions; Improves Clinical and Financial Outcomes 6Health News:Study of ancient and modern plagues finds common features 2Health News:Study of ancient and modern plagues finds common features 3Health News:Study of ancient and modern plagues finds common features 4
...ollege and hospital was a scene of pandemonium wit...octors initiating an outpatients’ department// on ...ents. The groups, under the name of ‘Youth for equ...ents have expressed consolation at the opening of ...
... to a recent survey it was found that people who w...cious about the way they look//. This resulted in ...TV programmes have also played their parts in crea... surgeries. Statistics show that there is a 40 % ...
... to a research it was found that radiotherapy give...ective against breast cancer//. The researchers fr...to be effective in the recurrence of cancer when c...ses. The findings were as a result of the 10-year ...
...study, Roche Holding AG (RHHBY), a Swiss pharmaceu...eases when Herceptin was added to hormonal therapy...-positive, as well as HER2-positive, this combined...receptor-positive breast cancer results lower risk...
Other Medicine News:
(Date:11/20/2008)...-FirstCall/ -- PAREXEL International Corporation (...al services provider, today announced that it has ...ry consulting and clinical research capabilities. ...has locations throughout five important biopharmac...de Argentina, Brazil, Chile, and Mexico. This expa...
(Date:11/19/2008)...chieve statistical significance , , ISELIN,...Corporation (Nasdaq: PARS ) today announced resu...l NanoEmulsion (NE) drug delivery technology formu... The multi-center, randomized, double-blinded, pl...ficacy of the Company,s 3% Diclofenac Diethanolami...
(Date:11/19/2008)...t from Roche- , , MONTVALE, N.J., Nov. 19 /...rp. (Nasdaq: MEMY ) today announced that it has ... of R3487/MEM 3454, its lead alpha-7 nicotinic rec...with schizophrenia (CIAS). The Company has random... a $5.0 million payment from its partner Roche. M...
(Date:11/18/2008)...Newswire-USNewswire/ -- Forty-two leading U. S. sc...tional forum to consider cutting-edge innovations ...al economy from outbreaks of dangerous zoonotic di... Among those innovations: , , , , ...le that detects highly contagious and dangerous zo...
Breaking Medicine Technology:PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 2PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 3PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru 4Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 2Memory Pharmaceuticals Achieves Enrollment Goal for Phase 2 Study of MEM 3454 in Cognitive Impairment Associated With Schizophrenia 342 Top U.S. Scientists and Specialists Explore Cutting-Edge Innovations to Defend America From Dangerous Zoonotic Diseases 2Providing toilets safe water is top route to reducing world poverty 3A UN University 5450 1Providing toilets safe water is top route to reducing world poverty 3A UN University 5450 2Providing toilets safe water is top route to reducing world poverty 3A UN University 5450 3Providing toilets safe water is top route to reducing world poverty 3A UN University 5450 4Providing toilets safe water is top route to reducing world poverty 3A UN University 5450 5iMedica Partners With LDM GROUP to Offer ScriptGuide to Physician Practice Customers 8359 1iMedica Partners With LDM GROUP to Offer ScriptGuide to Physician Practice Customers 8359 2iMedica Partners With LDM GROUP to Offer ScriptGuide to Physician Practice Customers 8359 3Antibiotics May Not Cause Diarrheal Bacteria 27262 1Antibiotics May Not Cause Diarrheal Bacteria 27262 2Healthcare Resources Available in Difficult Times 27258 1Healthcare Resources Available in Difficult Times 27258 2Healthcare Resources Available in Difficult Times 27258 3
...Mass.--(BUSINESS WIRE)--Jun 8, 2007 - Archemix Cor... and developing,aptamers, announced the successful...r therapeutic, ARC1779. ARC1779 is designed to,sel...ation of,platelets by inhibiting the binding of vo...platelets. Activated vWF is scientifically,recogni...
...MARGIN: 0in 0in 0pt; LINE-HEIGHT: 150%; mso-hyphen...oneering nasal spray,could stop thousands of patie...t was reported today1 at the 10th Congress of,the ..., 7–9,June. The study investigated whether t... fast onset of pain relief and short,duration of e...
Other Medicine Technology:Archemix Announces Completion of Phase 1 Trial of ARC1779 2Archemix Announces Completion of Phase 1 Trial of ARC1779 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 2Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 4Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 5Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 6
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: